Table 5.

Patient factors associated with the use of biologic DMARDs among children without systemic arthritis (N = 2,502).

Patient factor	Univariate OR (95% CI)	Multivariable OR (95% CI)
Extended oligoarthritis*	3.5 (2.6–4.8)	---
RF− polyarthritis*	4.7 (3.8–5.9)	1.9 (1.5–2.5)
RF+ polyarthritis*	8.6 (6.1–12)	3.4 (2.2–5.2)
Psoriatic arthritis*	5.7 (4.0–8.1)	2.7 (1.8–3.9)
ERA*	3.5 (2.6–4.7)	---
History ≥ 5 joints	3.7 (3.1–4.4)	2.3 (1.8–2.9)
HLA-B27	1.3 (1.0–1.8)	---
Uveitis	1.8 (1.4–2.3)	2.3 (1.7–3.0)
IBD	3.3 (1.8–6.0)	3.0 (1.4–6.4)
SI tenderness	1.9 (1.4–2.4)	1.7 (1.2–2.4)
Enthesitis	1.6 (1.3–2.1)	1.9 (1.4–2.6)
Psoriasis rash	2.0 (1.4–2.8)	---
CCP antibody	3.4 (2.3–5.2)	1.9 (1.1–3.2)
Radiographic damage	3.0 (2.5–3.7)	2.2 (1.7–2.8)
Disease duration (per year)	1.1 (1.1–1.2)	1.1 (1.1–1.1)

^*= compared to oligoarthritis category

RF = rheumatoid factor; ERA = enthesitis-related arthritis; IBD = inflammatory bowel disease; SI = sacroiliac; CCP = cyclic citrullinated peptide; OR = odds ratio; CI = confidence interval